NCT/Study#

NCT04649359 /

C1071003

AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF PF-06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY

AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF
PF-06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA
WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY

DISEASE GROUP:
Multiple Myeloma
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: